Zhejiang Conba Pharmaceutical (600572) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600572 Zhejiang Conba Pharmaceutical

Watchlist

4.42
+0.04+0.91%

Market Closed Jan 17 15:00 CST

11.42BMarket Cap23.51P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Zhejiang CONBA Pharmaceutical Gets Registration Approval for Asthma Relief Drug
MT NewswiresJan 17 03:33 ET
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Market Cap Dropped CN¥752m Last Week; Individual Investors Bore the Brunt
Simply Wall StJan 13 23:52 ET
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Simply Wall StDec 23, 2024 22:51 ET
CONBA Pharma Gets Regulatory Nod to Make Changes to Amikacin Sulfate Injection
MT NewswiresDec 4, 2024 00:47 ET
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Earnings Have Declined Over Five Years, Contributing to Shareholders 16% Loss
Simply Wall StNov 29, 2024 21:03 ET
Zhejiang CONBA Pharmaceutical Gets Approval for Hair Loss Cream in China
MT NewswiresNov 28, 2024 01:24 ET

Comments

Moomoo AI

Mar 16, 2024 20:12

Zhejiang CONBA Pharmaceutical's low P/E ratio is due to its poor earnings outlook. Shareholders accept this, anticipating no future earnings surprises. Without improvement, this will continue to hinder the share price.

Zhejiang CONBA Pharmaceutical Co.,Ltd.'s (SHSE:600572) Shares Lagging The Market But So Is The Business

Moomoo AI

Feb 5, 2024 23:35

The market's expectation for durable top line growth could explain the share price weakness. The company's performance last year may indicate unresolved challenges. Several warning signs could influence the company's future performance.

Investors Five-year Losses Continue as Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Dips a Further 4.8% This Week, Earnings Continue to Decline

Moomoo AI

Dec 8, 2023 16:49

Zhejiang CONBA Pharmaceutical's cash and EBIT growth point to its good position to handle any potential debt. Its strong cash conversion indicates a sturdy financial stance.

Does Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Have A Healthy Balance Sheet?

Moomoo AI

Oct 19, 2023 00:48

Despite share price gain, progress may not be reflected in EPS. Recorded TSR loss of 2% per year over last five years hints at potential risks, despite promising shareholder returns.